Is it time to buy shares in Australian Pharmaceutical Industries Ltd (ASX:API)?

Following the release of its full-year results, is it time to buy shares in Australian Pharmaceutical Industries Ltd (ASX: API)?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The share price of Australian Pharmaceutical Industries Ltd (ASX: API) has been on a roller coaster ride over the last 2 years. After reaching a high of $2.38 in May 2017, the company's shares were sold-off on fears that it would not meet profit expectations amid an increasingly difficult trading environment in its retail and pharmacy distribution businesses. Rival Sigma Healthcare Ltd (ASX: SIG) has fared even worse following the loss of its Chemist Warehouse supply contract.

After bottoming at $1.23 in late April 2018, shares of Australian Pharmaceutical Industries have enjoyed a bounce with the $127 million acquisition of Clearskincare Clinics in June leading to a re-rating.

Flat FY18

Last Thursday's release of the company's full-year numbers reaffirmed the tough conditions the company has faced in its core businesses. Australian Pharmaceutical Industries saw revenue fall 0.9% to $4,026 million in FY18, which management attributed to reduced demand for Hepatitis C medicines of around $155 million. The company noted that after excluding Hepatitis C medicines, revenue actually grew by 3.3% over the prior corresponding period.

Underlying EBITDA in FY18 decreased by 1.5% to $118.7 million primarily due to the impact of a rise in the number of price reduction cycles in the PBS and exclusive direct distribution arrangements. Statutory net profit after tax fell by 8.2% to $48.1 million for the period. However, this included one-off costs of $6.6 million from the Cleanskincare purchase and business restructuring expenses to lower the company's cost base. After backing out these costs, underlying net profit after tax was actually up 0.9% to $54.7 million.

Foolish takeaway

Australian Pharmaceutical Industries' share price is down 3% post-earnings to $1.67 at the close of Monday trade. The company posted underlying earnings per share of 11.1 cents in FY18, which sees it currently trading at a reasonable valuation multiple of around 15 times trailing earnings.

Management has indicated it expects growth in FY19 without providing an estimate. The company will wait for the vital Christmas trading period and the result of the Community Service Obligation review, which will examine exclusive supply arrangements among other things before providing further guidance to the market.

The acquisition of Clearskincare and the move into an adjacent market is something to watch as the company integrates the acquisition and expands its network. Nevertheless, the challenging trading environment in the company's core businesses remains a concern, and as such, I think there are better opportunities in other Australian healthcare companies such as CSL Limited (ASX: CSL) and ResMed Inc (ASX: RMD)

Motley Fool contributor Tim Katavic owns shares of CSL Limited. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

Macquarie's top 3 ASX stock picks in the healthcare sector

Top broker has revealed 3 healthcare stocks with upside. 

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 of the best ASX 200 healthcare shares to bring your portfolio to life

These shares could be just what the investment doctor ordered according to analysts.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Share Gainers

Guess which ASX All Ords stock just rocketed 28% on a new commercial contract!

The ASX All Ords stock has grabbed plenty of investor interest on Tuesday.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Is the CSL share price a buy? Here's a top broker's view

Is this stock a healthy opportunity? Let’s have a look.

Read more »

Man ecstatic after reading good news.
Healthcare Shares

Which ASX company has just secured FDA approval?

This stock just announced some big news.

Read more »

Health professional putting on gloves.
Healthcare Shares

How will Ansell shares navigate tariffs according to Macquarie?

The next two years could be a challenging period for the PPE company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is surging 18% on big news

This stock is getting a lot of love from investors on Monday.

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
Healthcare Shares

CSL shares are having a tough time recently. Are they a buy or a sell?

Is now a good time to jump in and buy this blue chip star?

Read more »